A New Candidate for Resurrection
Colossal Biosciences, the biotech company known for its ambitious plan to revive the woolly mammoth, has announced its next target: the bluebuck, or blue antelope. This striking animal, with a bluish-gray coat and long, straight horns, once roamed the grasslands of South Africa but was hunted to extinction by 1800.
Using genetic material from preserved specimens, Colossal plans to sequence the bluebuck genome and edit the DNA of a closely related living species—likely the roan antelope or sable antelope—to create a proxy. The goal is to produce a living animal that closely resembles the original bluebuck.
The Science of De-Extinction
Colossal's approach involves CRISPR gene editing to modify the genome of a surrogate species, then using cloning techniques to bring the embryo to term. The company has already made progress with the woolly mammoth, generating elephant stem cells and editing genes for cold tolerance.
For the bluebuck, the challenges include sourcing high-quality ancient DNA and ensuring the resulting animals can thrive in modern ecosystems. Colossal says it is working with conservation groups to identify suitable habitats.
Ethical and Ecological Debates
The de-extinction effort has sparked debate among scientists and ethicists. Supporters argue it could restore lost biodiversity and advance genetic medicine. Critics worry about unintended consequences, such as the impact on existing species and the diversion of resources from conservation.
Colossal maintains that its work contributes to conservation by developing technologies that can help save endangered species. The bluebuck project, if successful, would mark a significant milestone in the field.